Developer docs
API playgroundTry for free, no card

Search company profiles

Lightstone Ventures

Full company profile

uuid0000259

Namestring
Lightstone Ventures
Legal namestring
LSV Capital Management, LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Lightstone Ventures is a privately held life-sciences venture capital firm founded in 2012 to fund and build biotech and medtech companies developing first-in-class therapeutics and breakthrough medical devices. The firm invests across all modalities — small molecules, biologics, and cell/gene therapies — with therapeutic focus areas spanning central nervous system (CNS), autoimmune, oncology, ophthalmology, immunology, cardiovascular and neurology. Its investment approach is thesis-driven, hands-on and lifecycle-long, backing founders from start-up through commercialization with patient capital and operational partnership rather than purely financial sponsorship.

The firm operates through multiple specialized fund vehicles: a debut $172M US fund (2014), a €125M Ireland-focused fund (2014), a $50M Singapore-focused fund (2016), a $250M second life-sciences fund (2017) and a $375M third fund (2021) — its largest to date. Beyond fund vehicles, Lightstone maintains a strategic investment in 65LAB, a Singapore-based incubator partnered with Evotec that sources therapeutic IP from NUS, Duke-NUS and A*STAR, and a long-standing preferred partnership with The Foundry, the medical device incubator responsible for 20+ medtech companies including Ardian, Twelve and Evalve. Curie.Bio provides a complementary accelerator relationship for seed-stage therapeutics.

Lightstone monetizes through standard venture economics: management fees on committed capital across successive funds plus carried interest from portfolio exits. The track record includes 20 IPOs and 22 acquisitions across the portfolio — including notable realizations by Acceleron, ALX Oncology, Ardian (Medtronic), Plexxikon (Daiichi Sankyo), MicroVention (Terumo), Portola, Ra Pharma (UCB), Disarm Therapeutics (Lilly) and ZELTIQ. The team of ~18 named professionals spans Managing Partners Mike Carusi (Portola Valley) and Jean George (Boston), Partner Caroline Gaynor (Dublin), plus operating partners, advisors and a shared CFO function with affiliate firms Advanced Technology Ventures and Morgenthaler Ventures.

Short descriptiontext

Lightstone Ventures is a life-sciences venture capital firm founded in 2012 that funds and builds first-in-class biotech and medtech companies across the US, Ireland and Singapore, with ~$847M in cumulative committed capital, a 20-IPO/22-acquisition track record, and ~18 investment professionals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPortola Valley, United States
HQ citystring
Portola Valley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, biotech venture capital, medtech venture capital, life sciences funding, early stage healthcare investing
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAE
Financial Services / Fintech Growth Equity
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Life Sciences Investing
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture capital fund management
TypeManaged Services
Description

As a life sciences venture capital firm founded in 2012, Lightstone Ventures generates revenue through management fees on committed capital across multiple funds (including the legacy $172M fund, the $250M fund closed in 2017, the $375M third fund closed in 2021, and a $50M Singapore-focused fund closed in 2016) plus carried interest from successful portfolio company exits (20 IPOs and 22 acquisitions to date).

lightstonevc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
165LAB
Description

Singapore-based strategic investment / incubator partnered with Evotec to grow the pipeline of investible therapeutic companies from Singapore research institutions such as NUS, Duke-NUS and A*STAR.

lightstonevc.com
Core offering1 text field

Lightstone Ventures is a life sciences-focused venture capital firm that invests venture capital into biotech and medtech startups developing first-in-class drugs (small molecules, biologics, cell and gene therapies) and breakthrough medical devices. The firm manages multiple fund vehicles and deploys patient capital alongside hands-on operational partnership to build companies from start-up through commercialization and exit.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 20 IPOs and 22 Acquisitions across portfolio companies
+4 more records
Product overview1 text field

Lightstone Ventures is a venture capital firm (founded 2012) that operates a single unified platform offering of growth-stage venture capital across two industry verticals: Biopharma and Medtech. Its offering is structured as a portfolio of fund vehicles (the $375M Fund III, a prior $250M life-sciences fund, and a $50M Singapore-focused fund) plus dedicated incubators/accelerators — including the Singapore-based 65LAB strategic incubator (with Evotec) and its Curie.Bio partnership — that together fund and build biotech and medtech startups. The portfolio encompasses named active companies such as Cala Health (Cala kIQ / TAPS wearable neuromodulation for essential tremor and Parkinson's), Cerevance (NETSseq CNS drug discovery platform, Phase 3 solengepras), PsiThera (QUAISAR AI+molecular dynamics oral medicines), Nimbus Therapeutics (computationally designed SIK2 inhibitors and obesity programs), Alchemab Therapeutics (deep-learning antibody mining), Crystalys Therapeutics (dotinurad URAT1 inhibitor for gout), Atsena Therapeutics (ocular gene therapy ATSN-201), Tagworks Pharmaceuticals (Click-to-Release ADCs), Bonito Biosciences (RNA degrader oligos), Tallac Therapeutics (CpG-Antibody conjugates), Tizona/Trishula Therapeutics (anti-CD39 immuno-oncology), Carrick Therapeutics (samuraciclib breast cancer), MediSix Therapeutics (CAR-T for T-cell malignancies), Trotana (RNA-binding-protein medicines), Hydra Biosciences (ion-channel drugs); medtech actives including Apreo Health (Breathe Airway Scaffold for emphysema), Amber Therapeutics (adaptive neuromodulation for incontinence), FIRE1 (remote heart monitoring), Reprieve Cardiovascular (acute heart failure fluid management), CardiacBooster (percutaneous LVAD), SetPoint Medical (bioelectronic vagus nerve stimulation for autoimmune disease), Shoulder Innovations (InSet humeral stem), ProVerum (ProVee BPH system), Contego Medical (carotid/peripheral vascular), Relievant Medsystems (Intracept for low-back pain), Willow (wearable breast pump), EndoGastric Solutions (TIF/EsophyX GERD), Gynesonics (Sonata uterine fibroid ablation), Moximed (Atlas knee OA implant), Volta Medical (AI EP arrhythmia software), and Currie.Bio/65LAB as platforms. Realized exits include 20 IPOs (e.g., Acceleron, ALX Oncology, Cyteir, Vigil, Gemini, Ra Pharma, Flex Pharma, Portola, Five Prime, Verastem, Mersana, ZELTIQ) and 22 acquisitions (e.g., Ardian, MicroVention, Claret, PowerVision, Plexxikon, Twelve, Cabochon, Transcend, ForSight VISIONs, Proteolix, Hypnion, Disarm), reflecting the firm's integrated company-building and exit model across the biotech/medtech ecosystem.

Product and service7 records
1Lightstone Ventures Fund III ($375M Third Fund)
CategoryVenture Capital Fund
Description

Lightstone Ventures' $375 million third fund (closed September 2021), expanding the firm's thesis into the CNS field while continuing investments across biotech and medtech startups. Fund is structured as a limited partnership with capital called from institutional LPs over multiple years.

2Lightstone Ventures $250M Second Life Sciences Fund
CategoryVenture Capital Fund
Description

A $250 million life sciences venture capital fund closed in September 2017 to back biotech and medtech startups, building on the firm's US, Irish, and Singapore platforms.

3Lightstone Ventures Singapore Fund ($50M)
CategoryVenture Capital Fund
Description

A $50 million Singapore-focused fund closed in February 2016 to support medtech and biotech investments originating from Singapore-based research institutions such as NUS, Duke-NUS, and A*STAR.

4Lightstone Ventures $172M Debut Life Sciences Fund
CategoryVenture Capital Fund
Description

A $172 million debut US life sciences fund closed in 2014, focused on early-stage biotech and medtech startups; reported by FierceBiotech in 2014.

5Lightstone Ventures Ireland Fund (€125M)
CategoryVenture Capital Fund
Description

A €125 million Ireland-focused life sciences venture capital fund established in May 2014 to invest in innovative Irish life sciences firms.

665LAB Strategic Incubator
CategoryStrategic Incubator / Investment Vehicle
Description

Strategic investment in a Singapore-based incubator partnered with Evotec that grows the pipeline of investible therapeutic companies with technologies originating from Singapore research institutions such as NUS, Duke-NUS, and A*STAR. 65LAB funds promising early-stage therapeutic technologies to accelerate the drug development process and upon completion, projects are evaluated by 65LAB's board for further investment and the creation of new companies.

7Curie.Bio Founder Accelerator
CategoryStrategic Accelerator / Investment Vehicle
Description

Founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator that helps entrepreneurial founders launch viable therapeutics companies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagship PartnershipTypeStrategic or Co-development PartnerAnnounced on2017-09-01
Description

65LAB is a Singapore-based incubator in which Lightstone has made a strategic investment, partnered with Evotec. The purpose of 65LAB is to grow the pipeline of investible therapeutic companies with technologies originating from Singapore research institutions such as NUS, Duke-NUS and A*STAR. 65LAB funds promising early-stage therapeutic technologies to accelerate the drug development process; upon completion, projects are evaluated by 65LAB's board for further investment and the creation of new companies.

Strategic tierFlagship PartnershipTypeStrategic or Co-development PartnerAnnounced on1998-01-01
Description

The Foundry is the premier medical device company incubator and a preferred partner to LSV. Since its inception in 1998, The Foundry has founded and financed over twenty new medical device companies. Success stories include Evalve (acquired by Abbott), Concentric (acquired by Stryker), Ardian (acquired by Medtronic), Twelve (acquired by Medtronic). LSV partners Hanson S. Gifford III and Mark Deem are co-founders/managing partners of The Foundry.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Lightstone collaborates with Singapore's A*STAR as a key research institution from which 65LAB sources novel therapeutic technologies. Mike Carusi currently sits on the A*STAR Medtech Catapult Steering Committee.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Third Rock Ventures is a healthcare venture firm that founds and builds biotech companies from scratch. Its model of company creation, large founding teams, and focus on bold first-in-class science closely mirrors Lightstone's playbook (e.g., its co-founder Christina Isacson previously worked at Third Rock).

TypeBroad incumbent
Description

OrbiMed is one of the largest healthcare-dedicated investment firms globally, managing public and private equity, royalty, and credit strategies across the healthcare spectrum. As a broad incumbent, it competes with Lightstone in late-stage biotech and medtech but at a much larger AUM and with broader instrument coverage.

TypeDirect peer
Description

5AM Ventures is an early-stage life sciences venture capital firm focused on founding and seeding biotech companies. Its hands-on company-creation approach and focus on next-generation therapeutics closely parallels Lightstone's Lightstone-led newco strategy, particularly in CNS and rare disease.

TypeBroad incumbent
Description

RA Capital is a crossover life sciences investor combining public equity and private venture investing. Its TechAtlas research platform and crossover model make it a broad incumbent competing with Lightstone for biotech Series A/B rounds and at the public-market crossover.

TypeBroad incumbent
Description

NEA is one of the largest US venture capital firms with a dedicated healthcare practice investing across biotech, medtech, and digital health. As a broad incumbent, it competes with Lightstone across stages but at much greater AUM and with a broader sector mandate.

TypeBroad incumbent
Description

Flagship Pioneering is a biotechnology-focused venture creation firm that originates and grows platform companies such as Moderna. As a much larger broad incumbent, it competes with Lightstone for breakthrough biotech opportunities and founder talent, particularly in platform/AI-enabled drug discovery.

TypeDirect peer
Description

Atlas Venture is a life sciences-focused venture capital firm that builds biotech companies from inception. Like Lightstone, it focuses on early-stage biotech and medtech, pursues a hands-on company-building model, and has a strong exit track record — making it a direct peer in thesis and operating approach.

TypeBroad incumbent
Description

ARCH Venture Partners is a leading early-stage technology and life sciences VC firm, known for backing breakthrough biotech companies such as Illumina, Foundation Medicine, and Editas. Comparable to Lightstone in the biotech vertical but operates at meaningfully larger fund sizes and broader scope.

TypeDirect peer
Description

Versant Ventures is a healthcare-focused VC firm investing across biotech, medtech, and healthcare services with offices in the US, Canada, and Europe. Comparable to Lightstone in its dual biotech/medtech thesis, global footprint, and stage-agnostic deployment from inception through commercial-stage rounds.

TypeDirect peer
Description

Frazier Life Sciences is a dedicated life sciences venture capital firm investing across all stages of biotech and medtech development. Its thesis-driven approach, public/private crossover exposure, and stage-agnostic strategy closely parallel Lightstone's model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment91 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lightstone Ventures

Venture Capital / Life Sciences Investinglightstonevc.com

Lightstone Ventures is a life-sciences venture capital firm founded in 2012 that funds and builds first-in-class biotech and medtech companies across the US, Ireland and Singapore, with ~$847M in cumulative committed capital, a 20-IPO/22-acquisition track record, and ~18 investment professionals.

What Lightstone Ventures does

Lightstone Ventures is a privately held life-sciences venture capital firm founded in 2012 to fund and build biotech and medtech companies developing first-in-class therapeutics and breakthrough medical devices. The firm invests across all modalities — small molecules, biologics, and cell/gene therapies — with therapeutic focus areas spanning central nervous system (CNS), autoimmune, oncology, ophthalmology, immunology, cardiovascular and neurology. Its investment approach is thesis-driven, hands-on and lifecycle-long, backing founders from start-up through commercialization with patient capital and operational partnership rather than purely financial sponsorship.

The firm operates through multiple specialized fund vehicles: a debut $172M US fund (2014), a €125M Ireland-focused fund (2014), a $50M Singapore-focused fund (2016), a $250M second life-sciences fund (2017) and a $375M third fund (2021) — its largest to date. Beyond fund vehicles, Lightstone maintains a strategic investment in 65LAB, a Singapore-based incubator partnered with Evotec that sources therapeutic IP from NUS, Duke-NUS and A*STAR, and a long-standing preferred partnership with The Foundry, the medical device incubator responsible for 20+ medtech companies including Ardian, Twelve and Evalve. Curie.Bio provides a complementary accelerator relationship for seed-stage therapeutics.

Lightstone monetizes through standard venture economics: management fees on committed capital across successive funds plus carried interest from portfolio exits. The track record includes 20 IPOs and 22 acquisitions across the portfolio — including notable realizations by Acceleron, ALX Oncology, Ardian (Medtronic), Plexxikon (Daiichi Sankyo), MicroVention (Terumo), Portola, Ra Pharma (UCB), Disarm Therapeutics (Lilly) and ZELTIQ. The team of ~18 named professionals spans Managing Partners Mike Carusi (Portola Valley) and Jean George (Boston), Partner Caroline Gaynor (Dublin), plus operating partners, advisors and a shared CFO function with affiliate firms Advanced Technology Ventures and Morgenthaler Ventures.

Lightstone Ventures firmographics

Firmographics
Name
Lightstone Ventures
Legal name
LSV Capital Management, LLC
Website
https://lightstonevc.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Lightstone Ventures is a life-sciences venture capital firm founded in 2012 that funds and builds first-in-class biotech and medtech companies across the US, Ireland and Singapore, with ~$847M in cumulative committed capital, a 20-IPO/22-acquisition track record, and ~18 investment professionals.
Ownership category
akta.pro rank

Lightstone Ventures industry classification

Industry
Product category
Venture Capital / Life Sciences Investing
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAE
Financial Services / Fintech Growth Equity

Keywords

  • Venture capital investing
  • Biotech venture capital
  • Medtech venture capital
  • Life sciences funding
  • Early stage healthcare investing

Where Lightstone Ventures is headquartered

Location

Headquarters

HQ city
Portola Valley
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Lightstone Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Venture capital fund management: As a life sciences venture capital firm founded in 2012, Lightstone Ventures generates revenue through management fees on committed capital across multiple funds (including the legacy $172M fund, the $250M fund closed in 2017, the $375M third fund closed in 2021, and a $50M Singapore-focused fund closed in 2016) plus carried interest from successful portfolio company exits (20 IPOs and 22 acquisitions to date).

Go-to-market motion3 records

Marketing channels5 records

Lightstone Ventures product offering

Product offering

Core offering

Lightstone Ventures is a life sciences-focused venture capital firm that invests venture capital into biotech and medtech startups developing first-in-class drugs (small molecules, biologics, cell and gene therapies) and breakthrough medical devices. The firm manages multiple fund vehicles and deploys patient capital alongside hands-on operational partnership to build companies from start-up through commercialization and exit.

Product overview

Lightstone Ventures is a venture capital firm (founded 2012) that operates a single unified platform offering of growth-stage venture capital across two industry verticals: Biopharma and Medtech. Its offering is structured as a portfolio of fund vehicles (the $375M Fund III, a prior $250M life-sciences fund, and a $50M Singapore-focused fund) plus dedicated incubators/accelerators — including the Singapore-based 65LAB strategic incubator (with Evotec) and its Curie.Bio partnership — that together fund and build biotech and medtech startups. The portfolio encompasses named active companies such as Cala Health (Cala kIQ / TAPS wearable neuromodulation for essential tremor and Parkinson's), Cerevance (NETSseq CNS drug discovery platform, Phase 3 solengepras), PsiThera (QUAISAR AI+molecular dynamics oral medicines), Nimbus Therapeutics (computationally designed SIK2 inhibitors and obesity programs), Alchemab Therapeutics (deep-learning antibody mining), Crystalys Therapeutics (dotinurad URAT1 inhibitor for gout), Atsena Therapeutics (ocular gene therapy ATSN-201), Tagworks Pharmaceuticals (Click-to-Release ADCs), Bonito Biosciences (RNA degrader oligos), Tallac Therapeutics (CpG-Antibody conjugates), Tizona/Trishula Therapeutics (anti-CD39 immuno-oncology), Carrick Therapeutics (samuraciclib breast cancer), MediSix Therapeutics (CAR-T for T-cell malignancies), Trotana (RNA-binding-protein medicines), Hydra Biosciences (ion-channel drugs); medtech actives including Apreo Health (Breathe Airway Scaffold for emphysema), Amber Therapeutics (adaptive neuromodulation for incontinence), FIRE1 (remote heart monitoring), Reprieve Cardiovascular (acute heart failure fluid management), CardiacBooster (percutaneous LVAD), SetPoint Medical (bioelectronic vagus nerve stimulation for autoimmune disease), Shoulder Innovations (InSet humeral stem), ProVerum (ProVee BPH system), Contego Medical (carotid/peripheral vascular), Relievant Medsystems (Intracept for low-back pain), Willow (wearable breast pump), EndoGastric Solutions (TIF/EsophyX GERD), Gynesonics (Sonata uterine fibroid ablation), Moximed (Atlas knee OA implant), Volta Medical (AI EP arrhythmia software), and Currie.Bio/65LAB as platforms. Realized exits include 20 IPOs (e.g., Acceleron, ALX Oncology, Cyteir, Vigil, Gemini, Ra Pharma, Flex Pharma, Portola, Five Prime, Verastem, Mersana, ZELTIQ) and 22 acquisitions (e.g., Ardian, MicroVention, Claret, PowerVision, Plexxikon, Twelve, Cabochon, Transcend, ForSight VISIONs, Proteolix, Hypnion, Disarm), reflecting the firm's integrated company-building and exit model across the biotech/medtech ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

  • 65LAB: Singapore-based strategic investment / incubator partnered with Evotec to grow the pipeline of investible therapeutic companies from Singapore research institutions such as NUS, Duke-NUS and A*STAR.

Products and services

  • Lightstone Ventures Fund III ($375M Third Fund) Lightstone Ventures' $375 million third fund (closed September 2021), expanding the firm's thesis into the CNS field while continuing investments across biotech and medtech startups. Fund is structured as a limited partnership with capital called from institutional LPs over multiple years.
  • Lightstone Ventures $250M Second Life Sciences Fund A $250 million life sciences venture capital fund closed in September 2017 to back biotech and medtech startups, building on the firm's US, Irish, and Singapore platforms.
  • Lightstone Ventures Singapore Fund ($50M) A $50 million Singapore-focused fund closed in February 2016 to support medtech and biotech investments originating from Singapore-based research institutions such as NUS, Duke-NUS, and A*STAR.
  • Lightstone Ventures $172M Debut Life Sciences Fund A $172 million debut US life sciences fund closed in 2014, focused on early-stage biotech and medtech startups; reported by FierceBiotech in 2014.
  • Lightstone Ventures Ireland Fund (€125M) A €125 million Ireland-focused life sciences venture capital fund established in May 2014 to invest in innovative Irish life sciences firms.
  • 65LAB Strategic Incubator Strategic investment in a Singapore-based incubator partnered with Evotec that grows the pipeline of investible therapeutic companies with technologies originating from Singapore research institutions such as NUS, Duke-NUS, and A*STAR. 65LAB funds promising early-stage therapeutic technologies to accelerate the drug development process and upon completion, projects are evaluated by 65LAB's board for further investment and the creation of new companies.
  • Curie.Bio Founder Accelerator Founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator that helps entrepreneurial founders launch viable therapeutics companies.

Quantifiable outcome

  • 20 IPOs and 22 Acquisitions across portfolio companies
  • +4 more outcomes

Companies that use Lightstone Ventures

Customer profile

Segments2 records

Ideal customer profiles3 records

Lightstone Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lightstone Ventures partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship partnership and strategic.

  • Evotecflagship partnershipStrategic or Co-development Partner · 1 September 201765LAB is a Singapore-based incubator in which Lightstone has made a strategic investment, partnered with Evotec. The purpose of 65LAB is to grow the pipeline of investible therapeutic companies with technologies originating from Singapore research institutions such as NUS, Duke-NUS and A*STAR. 65LAB funds promising early-stage therapeutic technologies to accelerate the drug development process; upon completion, projects are evaluated by 65LAB's board for further investment and the creation of new companies.
  • The Foundry, LLCflagship partnershipStrategic or Co-development Partner · 1 January 1998The Foundry is the premier medical device company incubator and a preferred partner to LSV. Since its inception in 1998, The Foundry has founded and financed over twenty new medical device companies. Success stories include Evalve (acquired by Abbott), Concentric (acquired by Stryker), Ardian (acquired by Medtronic), Twelve (acquired by Medtronic). LSV partners Hanson S. Gifford III and Mark Deem are co-founders/managing partners of The Foundry.
  • A*STAR (Agency for Science, Technology and Research, Singapore)strategicStrategic or Co-development PartnerLightstone collaborates with Singapore's A*STAR as a key research institution from which 65LAB sources novel therapeutic technologies. Mike Carusi currently sits on the A*STAR Medtech Catapult Steering Committee.

Scale indicators5 records

Recent moves11 records

Expansion highlights5 records

Lightstone Ventures competitors and assessment

Company assessment

Direct peers

  • Third Rock Ventures: Third Rock Ventures is a healthcare venture firm that founds and builds biotech companies from scratch. Its model of company creation, large founding teams, and focus on bold first-in-class science closely mirrors Lightstone's playbook (e.g., its co-founder Christina Isacson previously worked at Third Rock).
  • 5AM Ventures: 5AM Ventures is an early-stage life sciences venture capital firm focused on founding and seeding biotech companies. Its hands-on company-creation approach and focus on next-generation therapeutics closely parallels Lightstone's Lightstone-led newco strategy, particularly in CNS and rare disease.
  • Atlas Venture: Atlas Venture is a life sciences-focused venture capital firm that builds biotech companies from inception. Like Lightstone, it focuses on early-stage biotech and medtech, pursues a hands-on company-building model, and has a strong exit track record — making it a direct peer in thesis and operating approach.
  • Versant Ventures: Versant Ventures is a healthcare-focused VC firm investing across biotech, medtech, and healthcare services with offices in the US, Canada, and Europe. Comparable to Lightstone in its dual biotech/medtech thesis, global footprint, and stage-agnostic deployment from inception through commercial-stage rounds.
  • Frazier Life Sciences: Frazier Life Sciences is a dedicated life sciences venture capital firm investing across all stages of biotech and medtech development. Its thesis-driven approach, public/private crossover exposure, and stage-agnostic strategy closely parallel Lightstone's model.

Broad incumbents

  • OrbiMed: OrbiMed is one of the largest healthcare-dedicated investment firms globally, managing public and private equity, royalty, and credit strategies across the healthcare spectrum. As a broad incumbent, it competes with Lightstone in late-stage biotech and medtech but at a much larger AUM and with broader instrument coverage.
  • RA Capital Management: RA Capital is a crossover life sciences investor combining public equity and private venture investing. Its TechAtlas research platform and crossover model make it a broad incumbent competing with Lightstone for biotech Series A/B rounds and at the public-market crossover.
  • New Enterprise Associates (NEA): NEA is one of the largest US venture capital firms with a dedicated healthcare practice investing across biotech, medtech, and digital health. As a broad incumbent, it competes with Lightstone across stages but at much greater AUM and with a broader sector mandate.
  • Flagship Pioneering: Flagship Pioneering is a biotechnology-focused venture creation firm that originates and grows platform companies such as Moderna. As a much larger broad incumbent, it competes with Lightstone for breakthrough biotech opportunities and founder talent, particularly in platform/AI-enabled drug discovery.
  • ARCH Venture Partners: ARCH Venture Partners is a leading early-stage technology and life sciences VC firm, known for backing breakthrough biotech companies such as Illumina, Foundation Medicine, and Editas. Comparable to Lightstone in the biotech vertical but operates at meaningfully larger fund sizes and broader scope.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

Lightstone Ventures social profiles

Digital presence

Lightstone Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lightstone Ventures leadership team

Management profile

Number of profiles

Profiles18 records

Lightstone Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Lightstone Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lightstone Ventures M&A and investment

M&A and investment

M&A

Investments91 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lightstone Ventures

What does Lightstone Ventures do?

Lightstone Ventures is a life sciences-focused venture capital firm that invests venture capital into biotech and medtech startups developing first-in-class drugs (small molecules, biologics, cell and gene therapies) and breakthrough medical devices. The firm manages multiple fund vehicles and deploys patient capital alongside hands-on operational partnership to build companies from start-up through commercialization and exit.

Is Lightstone Ventures a public or private company?

Lightstone Ventures is a private company. It is classified as management employee owned and is currently operating.

When was Lightstone Ventures founded?

Lightstone Ventures was founded in 2012. It employs 11 to 50 people.

Where is Lightstone Ventures based?

Lightstone Ventures is headquartered in Portola Valley, United States, in the North America region.

How does Lightstone Ventures make money?

One revenue line is on record: venture capital fund management.

Who are Lightstone Ventures's main competitors?

Direct peers on record are Third Rock Ventures, 5AM Ventures, Atlas Venture, Versant Ventures and Frazier Life Sciences. Broad incumbents are OrbiMed, RA Capital Management, New Enterprise Associates (NEA), Flagship Pioneering and ARCH Venture Partners.

Does Lightstone Ventures have an API?

No public API is recorded for Lightstone Ventures.

What industry is Lightstone Ventures in?

Lightstone Ventures's product category is Venture Capital / Life Sciences Investing. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineCrystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for GoutCrystalys Therapeutics closed a $130 million Series B financing led by Frazier Life Sciences to advance dotinurad, a once-daily oral URAT1 inhibitor for gout. The proceeds will support ongoing Phase 3 trials RUBY and TOPAZ and commercialization preparation. The company aims to bring a second-line treatment option to patients failing first-line therapies.FinSMEsCrystalys Therapeutics Raises $130M in Series B FundingCrystalys Therapeutics raised $130M in Series B funding led by Frazier Life Sciences. The company will use the funds for late-stage clinical development and commercialization preparation of dotinurad, a once-daily oral URAT1 inhibitor for gout. The lead candidate is in clinical development as a second-line therapy.FinSMEsAlchemab Therapeutics Extends Series A Financing with USD34MAlchemab Therapeutics raised £25M (USD$34M) in a Series A extension from British Business Bank, bringing total Series A funding to £109M. The funds will support its clinical pipeline and expand its proprietary antibody dataset to over a billion sequences.Longevity.TechnologyDopamine’s limits meet a new Parkinson’s betCerevance completed enrollment in its Phase 3 ARISE trial for solengepras, a non-dopaminergic Parkinson's drug targeting GPR6. The company closed an oversubscribed $20 million Series C, extending its runway to mid-2027. It expects topline results in Q3 2026.Longevity.TechnologyCereVance completes Phase 3 Parkinson’s trial enrollment, secures $20MCereVance completed enrollment in its Phase 3 ARISE trial of solengepras for Parkinson's disease and closed an oversubscribed $20 million Series C. The trial enrolled 341 patients across four countries, with topline data expected in Q3 2026. Proceeds are expected to fund operations through mid-2027.BioPharma DiveA Roivant spinout bets on AI-designed drugs for immune conditionsPsiThera, a biotech spinout from Roivant Sciences formerly known as Psivant Therapeutics, raised $47.5 million in a Series A funding round co-led by Lightstone Ventures and Samsara BioCapital, with participation from Roivant, YK Bioventures, and Eurofarma Ventures, to develop AI-designed oral medications targeting tumor necrosis factor (TNF) for autoimmune conditions. The company is leveraging artificial intelligence to convert injectable biologic drugs like Humira and Enbrel into oral forms that are cheaper to produce and easier to administer, with plans to select its lead program candidate next year. While AI-designed drugs have faced skepticism due to limited clinical success so far, PsiThera leadership maintains the technology could transform drug discovery despite early-stage challenges.PR NewswireLightstone Ventures Marks Year-to-Date 2025 Milestones for its Innovative Biotech and Medtech Portfolio CompaniesLightstone Ventures announced that its portfolio companies raised approximately $725 million in private financing rounds year-to-date through September 2025. The firm also highlighted the successful initial public offering of Shoulder Innovations on the NYSE and the appointment of H. Martin Seidel as an advisor to enhance strategic capabilities.MoomooLightstone Ventures 標誌着其創新生物技術和醫療技術投資組合公司在 2025 年至今的里程碑Lightstone Ventures highlighted its progress in 2025, including raising approximately $725 million through private financings and overseeing Shoulder Innovations' IPO on NYSE. The firm also announced leadership enhancements and team additions aimed at supporting its portfolio of biotech and medtech companies.The Business TimesLightstone Ventures, Temasek’s ClavystBio co-lead Allay Therapeutics’ US$57.5 million Series D fundingAllay Therapeutics raised US$57.5 million in a Series D funding round co-led by Lightstone Ventures and ClavystBio to support its registration trial for post-surgical pain management products. The investment included participation from existing investors such as New Enterprise Associates and Vertex Growth, alongside new investors like SGInnovate and EDBI. Additionally, drug manufacturer Maruishi Pharmaceutical expanded its licensing agreement with Allay Therapeutics to include South Korea and Taiwan.